National Progress Report 2025 Goal: Reduce estimated* new hepatitis B virus infections by ≥20%

National Progress Report 2025 Goal: Reduce estimated* new hepatitis B virus infections by ≥20%
Bar chart for years 2013-2023, charting estimated acute infections, starting at 19,800 in 2013, increasing to 20,700 by 2019. Target is 18,000 by 2023.
Index of indicators
Check on Green, indicating 'Met or exceeded current annual target' Met or exceeded current annual target Arrow on yellow, indicating 'Not Met - moved toward annual target' Moving toward annual target, but annual target was not fully met X on red, indicating 'Not met—no change or moved away from annual target' Annual target was not met and has not changed or moved away  from annual target

Source: CDC, National Notifiable Diseases Surveillance System
*The number of estimated viral hepatitis infections was determined by multiplying the number of reported cases by a factor that adjusted for underascertainment and underreporting (1–2).

Summary of Findings

The estimated number of new hepatitis B virus (HBV) infections has been relatively stable since 2015. In 2019, there were 20,700 estimated new infections, slightly below the 2019 target of 20,800 estimated infections.

Reduction needed to meet 2025 goal: A 13.0% reduction from the estimated number of new HBV infections in 2019 is needed to meet the 2025 goal of 18,000 estimated infections.

This reduction can best be achieved by

  • Promoting implementation of the child and adolescent and adult immunization schedules, provider education, strategic partnerships, and other measures.
  • Building capacity for states to collect and use a core set of surveillance data to detect populations at higher risk of infection and gaps in vaccination coverage.
  • Conducting prevention research to demonstrate how best to provide hepatitis B vaccination, testing, and treatment as part of a comprehensive set of interventions for persons who inject drugs.
  • Continuing to promote routine childhood vaccination schedules and vaccination of adults at increased risk for hepatitis B according to Advisory Committee on Immunization Practices (ACIP) Vaccine Recommendations and Guidelines.

Technical Notes

Data Sources: CDC, National Notifiable Diseases Surveillance System (NNDSS)

Numerator: Number of estimated new (acute) HBV infections

Denominator: Not applicable

Indicator Notes: (1) The NNDSS is a nationwide collaboration that enables all levels of public health to share notifiable-disease-related health information. Surveillance for viral hepatitis through NNDSS is based on case definitions developed and approved by the Council of State and Territorial Epidemiologists (CSTE) and CDC. Reported cases of acute viral hepatitis B are required to meet specific clinical and laboratory criteria. Estimated infections are based on laboratory-confirmed cases of acute viral hepatitis. Acute hepatitis B is reportable in all jurisdictions. Health care providers, hospitals, and/or laboratories report cases to the local or state health department, and states voluntarily submit reports or notify CDC of newly diagnosed cases of hepatitis B that meet the CSTE/CDC surveillance case definition. To account for underascertainment and underreporting, the number of reported cases is multiplied by 6.5. The methods for developing the multiplication factor are documented in Klevens, et al (2) with corrected multipliers developed by CDC (1).

Goal Setting: The 2025 goal of 18,000 estimated cases is consistent with CDC’s Division of Viral Hepatitis 2025 Strategic Plan and HHS’s Viral Hepatitis National Strategic Planexternal icon. Annual targets assume a constant (linear) rate of change from the observed baseline (2017 data year) to the 2025 goal (2023 data year).

Limitations: The number of estimated infections is based on a simple, probabilistic model for estimating the proportion of patients who were symptomatic, received testing, and were reported to health officials in each year (2). This constant multiplier may not account for variations over time in underreporting and underascertainment due to changes in public and provider awareness, laboratory and diagnostic techniques, and the definition of the condition.


  1. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance—United States, 2019. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2021. Available at:
  2. Klevens RM, Liu S, Roberts H, Jiles RB, Holmberg SD. Estimating acute viral hepatitis infections from nationally reported cases. Am J Public Health. 2014;104(3):482-7.